What is the ICD‑10‑CM code for cannabis use disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ICD-10-CM Code for Cannabis Use Disorder

The ICD-10-CM code for cannabis use disorder is F12, with specific subcodes depending on the clinical presentation and severity.

Code Structure

The F12 code family encompasses all mental and behavioral disorders due to cannabis use. The coding follows this pattern:

  • F12.1x - Cannabis abuse (mild cannabis use disorder)
  • F12.2x - Cannabis dependence (moderate to severe cannabis use disorder)
  • F12.5 - Cannabis-induced psychotic disorder
  • F12.9 - Cannabis use, unspecified

The "x" in the code represents additional specificity for the clinical condition (e.g., F12.10 for cannabis abuse, uncomplicated; F12.20 for cannabis dependence, uncomplicated).

Clinical Context

Cannabis use disorder is formally recognized in the DSM-5 and requires meeting at least 2 of 11 diagnostic criteria within a 12-month period 1. The disorder is characterized by:

  • Mild: 2-3 criteria met
  • Moderate: 4-5 criteria met
  • Severe: 6 or more criteria met

Key diagnostic features include using more cannabis than intended, difficulty cutting back, continued use despite problems, tolerance, and withdrawal symptoms (irritability, insomnia, headaches) 1.

Important Coding Considerations

For prescribed medical cannabis patients, a modified framework may be more appropriate. When patients use cannabis strictly as prescribed, tolerance and withdrawal criteria should be excluded, reducing the diagnostic criteria from 11 to 9 items 2. This distinction matters because applying standard 11-item criteria to compliant medical cannabis users significantly overestimates disorder prevalence (20% vs 9% for any CUD) 2.

Epidemiologic Trends

Recent data shows CUD prevalence has been rising substantially. Between 2006-2015, hospitalizations with primary diagnosis F12 doubled in Canada, with F12.5 (psychotic disorder) tripling and accounting for 48% of cannabis-related hospitalizations by 2015 3. In the U.S., CUD prevalence increased from 5.9% (2021) to 7.4% (2024), with consistent upward trends across all demographic subgroups 4.

The population-attributable risk fraction for cannabis use disorder associated with schizophrenia nearly tripled from 3.7% pre-legalization to 10.3% post-legalization in Ontario, Canada 5.

Clinical Pitfall

Do not confuse F12 (cannabis use disorder) with T40.7 (poisoning by cannabis), which is used for acute toxicity presentations rather than the disorder itself 6.

References

3
Research

Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006-2015.

Health promotion and chronic disease prevention in Canada : research, policy and practice, 2020

Related Questions

What are the recommended psychosocial and pharmacologic treatments for an adult who wants to stop using marijuana, including management of withdrawal symptoms?
What is the typical duration of effects after ingesting a cannabis edible gummy containing 10 mg THC, and how does this duration change with a micro‑dose gummy containing approximately 1.25 mg THC?
What are the recommended guidelines for discontinuing THC‑containing cannabis edibles before a scheduled procedure under local anesthesia?
Can tetrahydrocannabinol (THC) cause palpitations?
Can THC-containing edibles cause panic attacks and prolonged brain fog lasting several days?
What is the appropriate nystatin dosing regimen for an infant with oral thrush or candidal diaper dermatitis?
What are the clinical signs and symptoms of deep tissue pathology (e.g., deep‑tissue infection, deep‑vein thrombosis, pressure injury, decompression sickness)?
In a person struggling to achieve life goals and reporting persistent depression, is the diagnosis more likely an adjustment disorder or major depressive disorder with generalized anxiety disorder?
In a patient with small intestinal bacterial overgrowth (SIBO), can I safely include the green tops of scallions (green onions) while avoiding the white stalk, and use blue oyster mushrooms in a sauté with tofu, buckwheat or quinoa as a low‑FODMAP option?
Is it appropriate to bill CPT code 90836 (psychotherapy, 45 minutes) and CPT code 99213 (office visit for brief medication review) together for the same patient?
What is the risk of hyponatremia with terlipressin, and should it be avoided in a patient with a serum sodium of 124 mEq/L?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.